Here's Why You Should Retain CONMED Stock in Your Portfolio for Now

CONMED (CNMD) delivered a strong Q2, with revenues up 3% to $342.3M and adjusted EPS of $1.15, both surpassing guidance, fueled by robust General Surgery performance and a 120 bps gross margin expansion to 56.5%. The medical device manufacturer, benefiting from a high recurring revenue base and easing supply chain constraints, projects 7% earnings growth for fiscal 2025 and narrowed its revenue guidance to $1.356-$1.378 billion. Despite these operational tailwinds and a consistent track record of earnings beats, CNMD shares have significantly underperformed year-to-date, impacted by tariff headwinds expected to affect Q3 and Q4 EPS, alongside persistent regulatory and data security risks.

Analysis

CONMED Corporation (CNMD) demonstrated solid operational execution in its second quarter, with revenues growing 3% year-over-year to $342.3 million and adjusted EPS of $1.15, both exceeding guidance. This performance was driven by the General Surgery division, which outpaced Orthopedics, and highlighted by a 120 basis point expansion in adjusted gross margin to 56.5% from improved product mix and efficiency. Key growth contributors include the AirSeal platform, which benefits from a 92% recurring revenue profile and growing integration with Intuitive Surgical's robotic systems, and the Buffalo Filter product, which is experiencing double-digit growth propelled by new "smoke-free OR" legislation. Despite these fundamental strengths, a history of beating earnings estimates, and narrowed upward guidance for FY25 revenue ($1.356-$1.378 billion), the company's stock has significantly underperformed, declining 20% year-to-date. This disconnect is partly attributable to quantifiable headwinds, notably tariffs, which are projected to negatively impact EPS by 2 cents in Q3 and 7 cents in Q4, tempering margin expectations for the second half of the year.

Key Decisions for Investors

• Investors should assess the significant divergence between CONMED's strong operational performance and its 20% year-to-date stock decline, as this may present a valuation opportunity if the market has overly penalized the company for near-term tariff impacts.
• Monitor the penetration rate of the AirSeal system on Intuitive Surgical's new da Vinci 5 robot, as its expansion from the current 10-20% usage represents a key long-term growth catalyst for the high-margin General Surgery segment.
• Factor the company's specific guidance on tariff-related EPS headwinds for Q3 and Q4 into financial models to accurately project near-term profitability and potential margin pressure.
• While the company is designated a 'Hold', investors should note the easing supply-chain constraints and three consecutive quarters of double-digit growth in the Foot & Ankle business as signs of a stabilizing and recovering Orthopedics segment.